The Global Biologics and Biosimilars Market is poised for robust expansion through 2032, driven by patent expirations of blockbuster biologics, increasing approval of biosimilar versions in oncology and autoimmune therapies, and policy support from regulators like the FDA and EMA. Biosimilars of high-demand drugs such as Humira and trastuzumab support cost-effective treatment framewor... https://www.uniprismmarketresearch.com/verticals/healthcare/biologics-and-biosimilars